Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Dalpiciclib|DRUG: Pyrotinib|DRUG: Fulvestrant
Sponsor: Tianjin Medical University Cancer Institute and Hospital